Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease

Overview

The proposed research is designed to test the global hypothesis that inhaled corticosteroids (ICS), a therapy developed to treat asthma, will prevent vasoocclusive painful episodes in adults with Sickle Cell Disease (SCD) who wheeze, but do not meet criteria for a diagnosis of asthma. The specific aims of this proposal are 1) Conduct a feasibility study – a randomized controlled trial of ICS for adults with SCD who do not meet criteria for a diagnosis of asthma but report recurrent cough or wheezing, 2) Measure the effects of ICS on biological correlates of pulmonary inflammation (as determined by exhaled nitric oxide) and vascular injury (as determined by sVCAM) in SCD, and 3) Compare properties of traditional and Bayesian adaptive clinical trial design for therapeutic trials in SCD in preparation for designing a definitive trial of ICS. These aims have the potential to 1) change the standard of care for individuals with SCD and recurrent cough or wheeze, 2) provide insight into the pathogenesis of non-asthmatic wheezing in SCD and its response to treatment, 3) explore the suitability of innovative clinical trial designs to overcome the challenges that have hindered therapeutic innovation for SCD.

Full Title of Study: “Inhaled Mometasone to Promote Reduction in Vasoocclusive Events”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: November 2017

Interventions

  • Drug: Mometasone Furoate
    • inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks
  • Drug: Placebo
    • placebo training inhaler with the same instructions as the experimental group.

Arms, Groups and Cohorts

  • Experimental: Mometasone Furoate
    • 1 puff daily (220mcg) for 16 weeks
  • Placebo Comparator: Placebo
    • 1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo).

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants Who Completed Follow up
    • Time Frame: at 2 years
    • Feasibility is determined by calculating the proportion of randomized participants who complete follow up and a minimum of 30 pain diaries with good adherence to the study medication vs. the number enrolled.

Secondary Measures

  • Change in Exhaled Nitric Oxide (eNO)
    • Time Frame: Before ICS therapy begins and at 8 weeks post enrollment
    • Change in effects of inhaled corticosteroids (ICS) as measured by exhaled nitric oxide levels, which is the primary marker of pulmonary inflammation.
  • Change in Soluble Vascular Cell Adhesion Molecule (sVCAM) Level
    • Time Frame: Before ICS therapy begins and at 8 weeks post enrollment
    • Mean Change in effects of inhaled corticosteroids vascular injury, assessed by biomarker sVCAM as a surrogate for vascular injury.
  • Change in Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me)
    • Time Frame: baseline and week 20
    • Mean changes in ASCQ-Me (NHLBI developed a patient-reported Sickle Cell Disease (SCD) quality of life measurement tool) pain impact, at week 20 as compared to baseline. A reduction change on a 100-point scale indicated improved quality of life. ASCQ-Me uses a T-score metric (0-100) in which 50 is the mean of the reference population and 10 is the standard deviation (SD) of that population.
  • The Medication Adherence Report Scale
    • Time Frame: 20 weeks
    • The medication adherence report scale for asthma is a 10 question tool scored between 0 and 5, with full scale from 0 to 25, with higher scores indicating greater adherence
  • Change in the Numerical Rating Scale (NRS) for Pain
    • Time Frame: baseline and 20 weeks
    • Mean change in patient reported pain NRS score, full scale range 0- 10, higher score indicate more pain
  • Asthma Control Test
    • Time Frame: 8 weeks
    • Asthma control test, total score from 0-25, with higher score indicating more symptoms
  • Admissions or Visits to the Hospital
    • Time Frame: baseline through 8 weeks
    • Number of times participant visited the Emergency Department (ED) or was admitted to the hospital
  • Change in Reticulocytes Count
    • Time Frame: baseline and 8 weeks
    • Mean change in reticulocytes count – the number of new red blood cells.
  • Change in FEV1/FVC
    • Time Frame: baseline and 8 weeks
    • Mean change in FEV1/FVC at 8 weeks compared to baseline

Participating in This Clinical Trial

Inclusion Criteria

  • Age 15 or older – Sever SCD phenotypes (Hb SS and Sβthalassemia0) – A positive response to cough/wheeze questions Exclusion Criteria:

  • Patient carries a physician diagnosis of asthma – Patient is prescribed asthma medications – Patient is currently having a painful crisis (as defined by validated pain diary questions) – Patient has acute respiratory symptoms – Known hypersensitivity to milk proteins – Meets criteria for our operational diagnosis of asthma – More than 15 ED visits for pain over the preceding 12 months – Admitted or discharged from the hospital for SCD pain within the last 7 days

Gender Eligibility: All

Minimum Age: 15 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Jeffrey Glassberg
  • Collaborator
    • National Heart, Lung, and Blood Institute (NHLBI)
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Jeffrey Glassberg, Assistant Professor – Icahn School of Medicine at Mount Sinai
  • Overall Official(s)
    • Jeffrey Glassberg, MD, MA, Principal Investigator, Icahn School of Medicine at Mount Sinai

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.